

# London Platelet Action Group (LoPAG)

**Chair:** Ursula Wood

**Co-chair:** Tim Williams

| Attendee             | Hospital/Organisation              | Initials |
|----------------------|------------------------------------|----------|
| Ness Hayes           | NHSBT                              | NH       |
| Ursula Wood          | Guys & St. Thomas' NHS Trust       | UW       |
| Tim Williams         | King's College Hospital            | TW       |
| Nella Pignatelli     | NHSBT                              | NP       |
| Rebecca Patel        | Northwick Park Hospital            | RP       |
| Kirk Beard           | NHSBT                              | KB       |
| Sheelan Abdulah      | Univeristy College London Hospital | SA       |
| Molly Rutherford     | Guys & St. Thomas' NHS Trust       | MR       |
| Richard Turner       | NHSBT                              | RT       |
| Lubna Awas           | Univeristy College London Hospital | LA       |
| Kojo Adarkwah-Yiadom | Great Ormand Street Hospital       | KA       |

**Minutes secretary:** Nella Pignatelli

**Apologies:** None

----- Meeting starts -----

## **1. Welcomes**

UW welcomed everyone present at the meeting.

## **2. Platelet Issues and Data Insights**

*Presented by NH*

### **2.1. Introduction**

- NH introduced herself as a Facilitation Specialist for Blood Stocks Management Scheme (BSMS), having joined NHSBT in December.
- This was her first meeting with the group, and she acknowledged it had been some time since the last gathering.

- She reviewed previous presentations to ensure continuity and welcomed any feedback or suggestions for future sessions.

## **2.2 Key Observations from the Data**

- Overall platelet issues have increased over the past six months.
- London accounts for approximately 26% of national platelet issues, up by 1% since the last meeting.
- A Negative platelet issues have slightly decreased in London (down 2%), consistent with the national trend.
- NH thanked all hospital teams for their efforts, acknowledging that data entry is not the most glamorous task but is greatly appreciated.
- Slight variation noted in moderate hospitals, possibly influenced by the recent cyber attack—though the specific sites affected are unclear.

## **2.3 Hospital Activity Trends**

- Activity levels remain consistent across very high, high, moderate, and low user groups.
- Notable variation between very high users and others.
- Kidney Hospitals: Sustained drop in platelet issues since May last year, possibly due to a change in practice or patient needs.
- UCLH: Notable drop in A negative platelet usage from November 2024 to February 2025.
- Seasonal trends observed, with lower activity during summer months.
- Greater variation in low user groups due to smaller volumes.

## **2.4 Wastage and WAPI**

- London region WAPI is at 3.5%, lower than the national average.
- Despite a few months with slightly higher wastage, the overall trend is stable and commendable.
- Since July 2024, WAPI in low user groups has improved by 2%, though still outside target—indicating progress with room for further improvement.
- Top causes of wastage: stock expiry and medically ordered but not used.
- A downward trend in wastage observed compared to spring/summer 2024, suggesting improved practices.
- Very high and high users show a stable pattern.

- Moderate and low users show more variation, likely due to smaller volumes and practices such as stock sharing with larger NHS sites.

## **2.5 Demand Data and A Negative Platelets**

- Stock-holding units in London (e.g., Tooting, Colindale, Basildon) show higher A negative demand than the national average.
- The A negative donor population remains at 8%, presenting ongoing supply challenges.
- Larger hospitals tend to have lower A negative demand relative to total usage.
- Smaller hospitals may show higher A negative demand, possibly due to broader use across patient groups.
- Variation may reflect changes in stock selection or patient needs—local expertise is key to interpreting these shifts.
- Data presented on total and percentage HT demand, including breakdowns by blood group (e.g., O and B).
- Practices vary by hospital, influenced by clinical needs and local protocols.

## **2.6 Impact of Green Status and Final Remarks**

- On 10 February, NHSBT announced that all platelet groups had returned to green status.
- A concern raised in other UK regions was whether this would lead to increased ordering.
- Data from London shows no such spike in activity following the status change.
- The 17-day rolling average of platelet issues remained stable, with expected dips around Christmas and bank holidays.
- This suggests that London hospitals have maintained responsible ordering practices despite improved stock levels.

## **2.7 Discussion**

- TW and UW discussed the impact of NHSBT alerts on platelet ordering behaviour.
- NH noted that long-term changes in practice may persist post-alert, similar to COVID-related changes.
- KB raised a question about the use of A POS platelets alongside A NEG.
- RP confirmed temporary use of A POS during the alert but reverted to A NEG, especially for healing patients.

- No incidents were reported during the A POS usage period.
- RP highlighted low usage (approx. 10 units/month) and the need to transfer near-expiry stock to Norfolk Park.
- KB mentioned concerns about A NEG availability and suggested proactive planning, especially around Easter.
- TW proposed a survey to assess emergency stock practices across hospitals.
- UW agreed and suggested including questions on emergency stock and anti-D usage.
- NH confirmed BSMS will conduct a broader emergency planning survey later in the year, including platelet stock practices.
- Decision: No separate survey needed; rely on BSMS survey.
- UW proposed reissuing an information leaflet with updated anti-D data.
- RT emphasised the need for early planning due to the extended holiday period.
- Focus on ensuring adequate A POS emergency stock to meet potential demand spikes.
- TW observed a decrease in A NEG platelet usage at UCLH, the largest user.
- SA confirmed a slight drop, attributing it to:
  - Increased use of patient-specific group-matched platelets.
  - Seasonal factors such as Eid, Ramadan, and bank holidays, which reduced overall hospital activity.
  - Stock Practices
- UCLH typically uses A NEG or A POS for AB patients, avoiding AB platelets.
- TW suggested considering a proportion of AB platelets to reduce pressure on A NEG stock.
- SA acknowledged the logic but noted:
- A NEG is preferred due to its universal compatibility and availability.
- AB is rarely used, even for red cells.
- UW suggested allowing NHSBT to choose between A or AB platelets when ordering, to help balance stock.
- SA agreed to revisit the discussion internally, though current practice heavily favours A NEG due to familiarity and availability.

### **3. 2025 Planning**

#### **3.1 Educational Activities for 2025**

- At least one educational event (likely online, as in previous years).

- Two educational newsletters (aiming for three if feasible).

### **3.2 Survey Update:**

- Original survey idea passed to NHSBT.
- Open to suggestions for alternative survey topics.

### **3.3 Proposed Newsletter Topic: Platelet Shortage Learnings**

- UW proposed compiling a collection of successful initiatives from different trusts during the platelet shortages.
- Examples: reducing standing orders, switching to daily ordering, reducing A NEG usage.
- Aim: Share nationally to support preparedness and best practices.
- Plan:
  - Email lab managers and TP networks to gather input.
  - Discuss findings at the next TADG meeting (26 June).
  - Include in one of the 2025 newsletters.

### **3.4 Additional Educational Topics**

- RP suggested exploring wastage and shortage management further.
- UW noted potential future relevance of new platelet products and the need for guidance if launched.

### **3.5 Transfusion Thresholds & Clinical Practice**

- RP highlighted examples of over-transfusion and unclear practices, such as dual platelet transfusions.
- TW suggested the need to clarify ambiguous areas in existing BSH guidance.
- Agreed there is potential to raise these concerns with BSH for future updates.
- RP cited a haematology patient with cerebral haemorrhage and HLA antibodies, where a target of 100 was unrealistic.
- Another case involved two platelet units given simultaneously, which lacked clinical justification.
- TW and RP stressed the absence of clear written guidance on timing and dosage, calling for more explicit protocols.
- UW proposed a structured approach: allow two attempts to reach the threshold, then proceed with transfusion during the procedure only.
- General agreement that this approach should be formalised to support patient blood management and reduce unnecessary transfusions.

- Discussion on the need for explicit guidance on:
  - Maximum number of prophylactic platelet units.
  - Timing of transfusions (e.g., spacing doses 12 hours apart).
  - Managing patients who will not reach target thresholds despite multiple transfusions.
- RP referenced existing app guidance, noting it is often overlooked in practice.
- UW proposed drafting a formal letter to the BSH (British Society for Haematology) to request clearer guidance.
- Agreement to proceed with this as a second project, potentially supported by survey data.
- TW presented a draft poster aimed at improving confidence in cross-group platelet transfusions during shortages.

### **3.6 IT Infrastructure and Education**

- UW noted that many hospitals are focused on IT upgrades, limiting engagement with platelet education or innovation.
- Emphasis on the need to fix a date for an educational event.

### **3.7 Any other business**

- LA shared that a registrar at UCLH is auditing platelet use, supported by a “smart phrase” system to justify transfusions.
- The tool is inconsistently used and not fully integrated into EPIC but aims to improve documentation of appropriateness.
- UW raised the issue of post-transfusion review, questioning whether outcomes are routinely assessed and documented.
- RP and LA noted that reviews are typically only done for HLA-matched transfusions, and even then, not consistently.
- UW suggested including this in a letter to BSH, especially regarding outpatient transfusions given above threshold to prevent emergency admissions.
- Discussion on whether early transfusions in outpatients prevent hospital admissions or are unnecessary.
- LA acknowledged this is a grey area, often driven by nurse-led decisions outside formal therapy plans.
- KB suggested exploring whether data exists on outcomes of early/out-of-threshold transfusions and offered to liaise with colleagues to investigate further.

- UW to coordinate with NP to set a date in October for an education event.
- UW to contact NHSBT regarding upcoming developments and explore ways to encourage clinicians to document transfusion appropriateness.

#### 4. Actions:

| No. | Action  | By Whom     |
|-----|---|-------------|
| 1   | Stock Management Team to include questions on A NEG and A POS emergency stock in their upcoming survey                                | NH/SMS Team |
| 2   | Explore reissuing an information leaflet with anti-D usage data   | UW/NP       |
| 3   | Draft and send a request for platelet shortage initiatives to lab managers and TP networks  | UW          |
| 4   | Add platelet shortage learnings to the TADG agenda for 26 June  | UW/NP       |
| 5   | Explore potential topics for a second or third newsletter, including wastage and transfusion thresholds.                              | All         |
| 6   | Draft a formal letter to the BSH (British Society for Haematology) to request clearer guidance on dual platelet transfusions.         | UW          |
| 7   | Arrange an education event  | UW/NP       |
| 8   | Explore whether data exists on outcomes of early/out-of-threshold transfusions. KB to liaise with colleagues to investigate further.  | KB          |
| 9   | UW to contact NHSBT regarding upcoming developments and explore ways to encourage clinicians to document transfusion appropriateness. | UW          |